Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients
| Autor: | Finn Sellebjerg, Helle Bach Søndergaard, PS Sorensen, P. E. H. Jensen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Myxovirus Resistance Proteins Multiple Sclerosis Enzyme-Linked Immunosorbent Assay Real-Time Polymerase Chain Reaction Antibodies Young Adult GTP-Binding Proteins Gene expression medicine Humans Immunologic Factors Luciferase RNA Messenger Messenger RNA biology business.industry Reverse Transcriptase Polymerase Chain Reaction Multiple sclerosis RNA Interferon-beta Middle Aged medicine.disease Antibodies Neutralizing Titer Real-time polymerase chain reaction Neurology Immunology biology.protein Female Neurology (clinical) Antibody business |
| Zdroj: | European journal of neurology. 19(10) |
| ISSN: | 1468-1331 |
| Popis: | Background and purpose Measurements of binding antibodies (BAbs), neutralizing antibodies (NAbs) and MX1 mRNA expression are used to analyse the immunological reactions in patients with MS treated with IFN-β. The correlations between these are yet not fully understood. Methods We measured BAbs and NAbs to IFN-β in 110 serum samples from 83 patients with MS treated with IFN-β, and in a subgroup, antibody titre was compared with corresponding expressions of MX1 mRNA. The methods used were capture ELISA assay, luciferase reporter gene assay and mRNA RT-PCR for MX1 gene expression. Results There were significant correlations between binding, neutralizing and MX1 results. Cut-off values are suggested for the definition of samples of BAbs and NAbs as negative, positive and grey zones. Naturally occurring groups of low and high antibody titres were identified by the correlation between BAbs and NAbs, probably as a result of an immunological maturation process of antibodies. The low-titre group had lower correlations between BAbs and NAbs than the high-titre group. Conclusions High correlation is demonstrated between the results obtained by the three methods, and we suggest the possibility of using ELISA measurements of BAbs to identify patients with high titres of anti-IFN-β antibodies that block the biological response to IFN-β. Ιn patients with low titres, we suggest to supplement ELISA with measurement of MX1 mRNA to establish whether the bioavailability of IFN-β is preserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text